Share on StockTwits

NxStage Medical (NASDAQ:NXTM) CEO Jeffrey H. Burbank unloaded 5,000 shares of the stock on the open market in a transaction dated Thursday, August 7th. The stock was sold at an average price of $14.00, for a total value of $70,000.00. Following the completion of the sale, the chief executive officer now directly owns 833,803 shares of the company’s stock, valued at approximately $11,673,242. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Piper Jaffray raised their price target on shares of NxStage Medical from $16.00 to $18.00 in a research note on Friday. Analysts at Canaccord Genuity raised their price target on shares of NxStage Medical from $19.00 to $20.00 in a research note on Friday. They now have a “buy” rating on the stock. One research analyst has rated the stock with a sell rating and one has assigned a buy rating to the company. NxStage Medical has an average rating of “Hold” and an average target price of $18.25.

Shares of NxStage Medical (NASDAQ:NXTM) traded down 1.64% on Friday, hitting $13.76. The stock had a trading volume of 374,718 shares. NxStage Medical has a 52-week low of $8.77 and a 52-week high of $15.65. The stock’s 50-day moving average is $13.76 and its 200-day moving average is $13.28. The company’s market cap is $845.1 million.

NxStage Medical (NASDAQ:NXTM) last announced its earnings results on Thursday, August 7th. The company reported ($0.12) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.11) by $0.01. The company had revenue of $74.10 million for the quarter, compared to the consensus estimate of $70.52 million. During the same quarter last year, the company posted ($0.06) earnings per share. NxStage Medical’s revenue was up 13.3% compared to the same quarter last year. On average, analysts predict that NxStage Medical will post $-0.42 earnings per share for the current fiscal year.

NxStage Medical, Inc (NASDAQ:NXTM) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.